Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 17, Issue 11, Pages 1433-1438Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2017.1366444
Keywords
Natalizumab; Crohn's disease; efficacy; safety; progressive multifocal leukoencephalopathy
Funding
- National Institutes of Health via the National Institute of Diabetes and Digestive and Kidney Diseases [DK042191, DK055812, DK091222, DK097948]
Ask authors/readers for more resources
Introduction: Amongst the available therapies for moderate to severe Crohn's disease (CD) patients who are refractory to conventional therapy, anti-TNF blockers are the most effective biological treatment option. However, many patients experience a primary or secondary non-response to anti-TNF therapy, creating the need for alternative biological drugs that target different mechanisms of action and inflammatory pathways. Natalizumab, the first non-anti-TNF biological drug to be approved for treatment of CD patients, is a recombinant humanized antibody that targets the (4)-subunit of both (41) and (47) integrins, thus preventing activated leukocyte homing to the intestinal mucosa.Areas covered: This article summarizes the pathophysiological background and the efficacy and safety data of natalizumab, as well as the regulatory issues surrounding it.Expert opinion: Natalizumab represents an effective therapy for refractory CD patients. However, the rare but serious event of progressive multifocal leukoencephalopathy occurrence has compromised its widespread use. The subsequent advent of more specific anti-integrin drugs (i.e. vedolizumab) that carry a more favorable safety profile further reduces the clinical indications for natalizumab. The regulatory process for natalizumab distribution and monitoring in the US may provide a forum for discussion on how to optimally manage use of drugs that offer clinical benefits to patients, while minimizing associated risks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available